)
Edge11 Sep 2026
Texas Pacific Land Corporation: Keeper of the Permian Basin
Land once granted to a failed 19th-century railroad now generates royalties for Texas Pacific Land Corporation across the Permian Basin.
Castle Biosciences
Castle Biosciences (CSTL) investor relations material
Castle Biosciences 2026 Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.2026 Global Healthcare Conference summary15 Sep, 2026
Business overview and recent performance
Focuses on molecular diagnostics with tests impacting physician decisions and patient outcomes in dermatology and gastroenterology.
Main revenue drivers are melanoma and TissueCypher tests, both showing strong progress and sector-leading adjusted gross margins.
No changes in long-term outlook for 2026; macro environment and inflation remain stable.
TissueCypher growth and market dynamics
TissueCypher test volumes grew 63% year-over-year, with expectations for 50%-52% annual growth.
Penetration is early; adoption increases as practices standardize use, with workflow integration being key.
Addressable market is 415,000 patients annually, with current penetration at 10%-12%, aiming for mid-teens by year-end.
No lab capacity constraints; Pittsburgh lab is scaled ahead of demand.
Long-term penetration modeled at 60%-65% of the addressable market.
Commercial and operational strategy
Expanded gastroenterology sales territories; full productivity expected by 2027 after recent hiring.
New reps reach full productivity in about six months.
Most payers lack formal policies for TissueCypher; broader adoption is needed for coverage.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Castle Biosciences
- Growth in core tests and new launches, with positive EBITDA outlook through 2027.CSTL
Canaccord Genuity's 46th Annual Growth Conference - Q2 2026 saw 32% core test volume growth, $103.5M revenue, and raised annual guidance.CSTLCorporate presentation
- Q2 2026 revenue up 20% to $103.5M; core test volumes rose 32% and guidance was raised.CSTLQ2 2026
- Raised 2026 guidance after strong Q1 growth and expanded diagnostic test adoption.CSTLJefferies Global Healthcare Conference 2026
- Q1 2026 revenue hit $83.7M, core test volumes rose 36%, and guidance increased to $345–355M.CSTLQ1 2026
- Strong clinical evidence and financial growth support expansion and pipeline innovation.CSTLCorporate presentation
- Q2 revenue up 74% to $87M; guidance raised to $275–300M on strong growth and margin gains.CSTLQ2 2024
- Q3 2024 revenue up 39% to $85.8M, guidance raised on strong test adoption and profitability.CSTLQ3 2024
- Q1 revenue up 21%, guidance raised, Previse acquired, IDgenetix discontinued, SCC risk remains.CSTLQ1 2025
Next Castle Biosciences earnings date
Q3 20262 Nov, 2026
Castle Biosciences
Next Castle Biosciences earnings date
Q3 20262 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage